Regeneron (REGN) Reports Updates on Phase 3 Libtayo (cemiplimab) Development Program in Advanced NSCLC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Regeneron Pharma (REGN) PT Raised to $352 at BMO Capital
November 5, 2019 3:43 PM ESTBMO Capital analyst Matthew Luchini raised the price target on Regeneron Pharma (NASDAQ: REGN) to $352.00 (from $344.00) while maintaining a Market Perform rating.
The analyst commented, "Regeneron reported a top- and bottom-line beat reflecting a combination of Eylea, Dupixent and another profitable quarter for the... More
Regeneron (REGN) Tops Q3 EPS by 31c, Offers FY Guidance
November 5, 2019 6:32 AM ESTRegeneron (NASDAQ: REGN) reported Q3 EPS of $6.67, $0.31 better than the analyst estimate of $6.36. Revenue for the quarter came in at $2.05 billion versus the consensus estimate of $1.99 billion.
2019 Financial... More
